

Executive Summary

A Collaborative Working Project between Bristol-Myers Squibb Pharmaceuticals Limited (“BMS”) and Clatterbridge Cancer Centre (“CCC”) NHS Foundation Trust

Name of Project	National Immuno-Oncology (IO) Clinical Network – bringing together IO Clinical Leaders as a National Clinical Network to champion and direct IO Service Development (“Project”)
Project Background	<p>The original idea of an IO Clinical Network came from initially an informal network of clinicians who saw the need to be more structured and to organise themselves to address the key issues in managing Immunotherapy in the UK – this included improving patient experience by providing outstanding specialist care for patients.</p> <p>In 2021 BMS hosted a roundtable in collaboration with the Health Service Journal (HSJ) which noted that treatments for cancer were rapidly evolving and potentially offering better outcomes, however quickly transferring breakthroughs into clinical practice remains challenging. There are often questions about how best to quickly implement new ways of doing things uniformly across an organisation – and indeed beyond, across a service.</p> <p>One of the outputs from the roundtable was the recognition of the need of a national forum where ideas can be shared, and information made easily accessible. Since the roundtable this idea has evolved and has been driven by Clatterbridge Cancer Centre and a small group of oncology colleagues around the country. At a scoping meeting in March of this year there was a consensus that the newly formed IO Clinical Network would be an independent group of practitioners with five key pillars of focus: Service Development, Clinical Governance, Policy, Medical Education and Research.</p> <p>Before the ambition of a formal IO Clinical Network can be recognised, there needs to be an infrastructure in place so that they can carry out their activities and accept new members into the network. With this in mind both parties are looking to form a six-month Collaborative Working Project that will establish the infrastructure needed to enable the IO Clinical Network to become an autonomous organisation by the end of the project. BMS will share their experience of running forums like this and will work alongside Clatterbridge ensuring that they have the right policies and procedures in place. Throughout the partnership and the project Clatterbridge will implement the deliverables defined in the project objectives with BMS coaching and facilitating in the background.</p>
Project Objectives	<p>Project Aim</p> <ul style="list-style-type: none">• The aim of this Project is for both parties to work together to support the setting up and development of the IO Clinical Network and for it to be autonomous by the end of the six (6) months of the Project. The

	<p>project’s scope does not include the actual execution of any of the IO Clinical Network activities.</p> <p>Project Objectives</p> <ul style="list-style-type: none"> • To identify an NHS Project Management Team to manage the IO Clinical Network throughout 2022 and into 2023; defining roles and responsibilities and clear action steps to achieve Project aim. • Initial assessment of what processes and procedures are in place, identifying which of these are working well, where there are opportunities to improve, and if there are any gaps • For the NHS IO Clinical Network Project Manager to have a comprehensive project workbook which will include: <ul style="list-style-type: none"> • Stakeholder Management • Communication Plan • Project Plan and Timelines
Project Structure and Deliverables	<p>The key to this Project will be the collaboration between both parties to ensure that the right mechanisms are in place so that all three (3) deliverables can support the delivery and independence of the IO Clinical Network. This will allow the IO Clinical Network to run effectively and efficiently beyond the Project – quarterly meetings will be organised and delivered by the NHS and the IO Clinical Network and the outcomes/key messages from these will be communicated to centres across the UK allowing best practice to be shared.</p> <p>Both parties will initially identify and evaluate the current mechanisms that the NHS have in place.</p> <p>Where current mechanisms are working well the parties will look to develop and enhance their functionality and outputs and where there are gaps or short falls the BMS Project Manager will work with the CCC Project Manager identifying and choosing alternatives before coaching* through processes and practicalities, where appropriate.</p> <p>The Project Board will continually monitor the above approach ensuring that the solutions in place for the three (3) deliverables are both fit for purpose and effective and that the IO Clinical Network is heading towards its aim of being autonomous by the end of the Project.</p> <p>*The GROW model of coaching will be adapted and used throughout this Project (Grow, Reality, Options, Way Forward).</p> <p>Project Inputs</p> <p>Resources will be pooled from both parties – these will include people, expertise, and project templates. There will be no financial contributions from either party.</p>
Project Benefits	<ul style="list-style-type: none"> • Benefits for Patient <ul style="list-style-type: none"> ○ More patients receive evidence-based care ○ More information about conditions and treatment options ○ Health inequalities reduced • Benefits to the NHS

	<ul style="list-style-type: none"> ○ Improved access to education and information ○ Efficiency and systems challenges addressed ● Benefits to BMS <ul style="list-style-type: none"> ○ Benefits to BMS Increase in the appropriate use of medicines aligned to local or national guidance ○ Better understanding of the challenges faced by healthcare organisations including the NHS via the monthly project meeting
Stakeholders	<ul style="list-style-type: none"> ● Clatterbridge Cancer Centre (“Clatterbridge”) ● Bristol-Myers Squibb Pharmaceuticals Limited (“BMS”)
Project Outcomes	<p>The aim of this Project was for BMS to offer support where needed in the setting up and development of the IO Clinical Network and for it to be autonomous by the end of the 2023;</p> <ul style="list-style-type: none"> ● The IO Clinical Network has now received Charitable Status <ul style="list-style-type: none"> ○ Their mission is to build an IO community to improve patient care ○ A network for all healthcare professionals caring for patients receiving immunotherapy ● A Board of Trustees has been appointed ● Five key areas have defined; <ul style="list-style-type: none"> ○ Education and Training (Lead Dr Ricky Frazer) ○ Clinical Support (Dr Kate Young) ○ Service Development (Dr Olsson-Brown) ○ Research and Analysis (Dr Brent O’Carrigan) ○ Policy and Governance (Dr Clare Barlow) ● The IO Clinical Network Website is up and running and continuing to develop ● Members can join the IO Clinical Network either through the website or via a dedicated email address ● The IO Clinical Network now has an established social media presence on X (Twitter) ● The IO Clinical Network have launched their own podcast – ImmunoBuddies – hosted by Dr Ricky Frazer and Dr Olsson-Brown ● The IO Clinical Network have hosted a number of webinars; <ul style="list-style-type: none"> ○ The first focusing on launching the network ○ The others focusing on specific areas; <ul style="list-style-type: none"> ▪ Pneumonitis ▪ Myocarditis ▪ Hepatitis
Project Conclusion	<p>By the end of 2023/beginning of 2024 the IO Clinical Network had received Charitable Status and through this had defined the way they were working through a series of processes and policies. It had an established Board of Trustees/Executive Board with a nominated Chief Executive Office (Dr Olsson-Brown) and a Director of Operations (Dr Alex Johnson). The Network has a healthy growing membership with both a developing website and a social media presence.</p>

